Syndax Pharmaceuticals filings document regulatory disclosures for a commercial-stage cancer-therapy company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary financial information, product-revenue updates for Revuforj and Niktimvo, business presentations and material product events, including the FDA approval of Revuforj for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation.
The company’s proxy materials cover board elections, executive compensation, equity-award valuation and shareholder voting matters. Other material-event filings address governance changes, including director departures, and Regulation FD disclosures tied to investor presentations and operating updates.
Proposed sale of Common Stock by an affiliate was reported. The notice lists 11,565 shares referenced with an open market entry dated 05/16/2025, 200 shares from restricted stock vesting on 05/16/2025, and 22,515 shares tied to a stock option exercise on 06/11/2026.
Syndax Pharmaceuticals, Inc. issued $250.0 million of 2.25% Convertible Senior Notes due 2031 in a private placement to institutional investors. The notes were issued under an indenture with U.S. Bank Trust Company, National Association, as trustee.
Net proceeds were approximately $243.0 million after fees and expenses, which Syndax expects to use for general corporate purposes, including working capital, research and development, commercialization activities and business development. The notes and any conversion shares were sold relying on registration exemptions under Sections 4(a)(2) and 3(a)(9) of the Securities Act.
Based on an initial maximum conversion rate of 54.5256 shares per $1,000 principal amount, up to 13,631,400 shares of common stock may initially be issuable upon conversion, subject to customary anti-dilution adjustments.
Syndax Pharmaceuticals, Inc. reported results from its June 10, 2026 annual stockholder meeting, where all proposals passed. Stockholders approved the 2026 Equity Incentive Plan, which reserves 7,200,000 shares of common stock plus shares that may return from expired or forfeited awards under the prior 2015 plan.
They also approved a new 2026 Employee Stock Purchase Plan to replace the 2015 plan, with U.S. and non-U.S. components, both effective June 10, 2026. Stockholders elected all nominated directors, gave advisory approval to executive compensation, and ratified the company’s independent public accounting firm.
Syndax Pharmaceuticals has entered into privately negotiated subscription agreements to issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a private placement, with expected net proceeds of about $243 million.
The notes are senior unsecured, pay 2.25% interest semiannually starting December 15, 2026, and mature on June 15, 2031, unless earlier converted, redeemed or repurchased. They are initially convertible at 40.3894 shares of common stock per $1,000 principal (an effective conversion price of about $24.76 per share), representing a roughly 35% premium to the June 3, 2026 share price. Under a higher maximum conversion rate of 54.5256 shares per $1,000, up to 13,631,400 shares may be issued.
Syndax may redeem the notes for cash on or after June 20, 2029 if its stock trades at least 130% of the conversion price for a specified period. Noteholders have conversion and repurchase rights upon certain trading, corporate or “fundamental change” events. The company plans to use proceeds for general corporate purposes, including working capital, research and development, commercialization and business development.
Syndax Pharmaceuticals Inc Chief Financial Officer Keith A. Goldan reported an open-market sale of 1,177 shares of common stock at $18.99 per share. According to the footnote, these shares were required to be sold to cover tax withholding obligations from the vesting of restricted stock units. Following the transaction, he held 139,252 shares directly, indicating this was a small, tax-related adjustment rather than a large discretionary sale.
Syndax Pharmaceuticals Chief Executive Officer Michael A. Metzger sold 6,847 shares of common stock in an open-market transaction. The shares were sold at an average price of $18.99 per share. According to the footnote, this sale was made to cover tax withholding obligations tied to vesting restricted stock units, and he continues to hold 484,843 shares afterward.
Point72 reports shared beneficial ownership of Syndax Pharmaceuticals common stock. As of the close of business on March 31, 2026, Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen are reported to beneficially own 1,985,547 shares, representing 2.3% of the class. The filing states the reported position reflects shared voting and shared dispositive power of 1,985,547 shares and that the reporting persons own no shares directly.
The statement lists the filing entities and their roles: Point72 Asset Management (investment manager), Point72 Capital Advisors Inc. (general partner), and Mr. Cohen (controls both). The address for the reporting persons is provided as 72 Cummings Point Road, Stamford, CT 06902. The filing is an amendment to a Schedule 13G and reflects holdings reported for disclosure purposes.